MED15 and renal cell carcinoma: In the specific context of renal cell carcinoma, MED15 has been identified as a fusion partner of TFE3 in a rare subtype, suggesting that aberrant activation of the TFE3-MED15 fusion protein may contribute to tumorigenesis (57).